Brief: Lyell Immunopharma Reports Recent Business Highlights, Third Quarter Financial Results
08/11/2022 23:22
Nov 8 (Reuters) - Lyell Immunopharma Inc LYEL.O :
* LYELL IMMUNOPHARMA REPORTS RECENT BUSINESS HIGHLIGHTS AND
THIRD
QUARTER FINANCIAL RESULTS
* LYELL IMMUNOPHARMA - CASH, CASH EQUIVALENTS AND MARKETABLE
SECURITIES OF $750.7 MILLION AS OF SEPTEMBER 30, 2022
* LYELL IMMUNOPHARMA - CASH RUNWAY EXTENDS FUNDING INTO 2026
AND
SUPPORTS ADVANCEMENT OF MULTIPLE PRODUCT CANDIDATES THROUGH KEY
CLINICAL MILESTONES
Source text for Eikon: ID:nGNX1CbyvH
Further company coverage: LYEL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lyell Immunopharma
See all newsBrief: Lyell Immunopharma Says Additional Clinical Data And End-Of-Phase 1 FDA Meeting Expected In 2027
Lyell Immunopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Lyell Immunopharma, Inc. expected to post a loss of $2.08 a share - Earnings Preview
Brief: Lyell Immunopharma Q2 Operating Expenses USD 47.341 Million
Brief: Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma